Lexicon Pharmaceuticals Inc (LXRX)vsNovartis AG ADR (NVS)
LXRX
Lexicon Pharmaceuticals Inc
$1.85
-2.12%
HEALTHCARE · Cap: $835.09M
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 81140% more annual revenue ($56.58B vs $69.64M). NVS leads profitability with a 23.9% profit margin vs -37.5%. NVS earns a higher WallStSmart Score of 49/100 (D+).
LXRX
Avoid29
out of 100
Grade: F
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LXRX.
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1572.0% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -12.9% — below average capital efficiency
Earnings declined 63.4%
Negative free cash flow — burning cash
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : LXRX
The strongest argument for LXRX centers on Revenue Growth, Debt/Equity. Revenue growth of 1572.0% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : LXRX
The primary concerns for LXRX are Market Cap, Return on Equity, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
LXRX profiles as a hypergrowth stock while NVS is a declining play — different risk/reward profiles.
LXRX carries more volatility with a beta of 1.07 — expect wider price swings.
LXRX is growing revenue faster at 1572.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 29/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lexicon Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in The Woodlands, Texas.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?